Ashutosh jain

🚨 Immunotherapy finally showing promise in pancreatic cancer? A randomized Phase II trial published in JCO suggests that adding toripalimab to mFOLFIRINOX improves outcomes in borderline resectable and locally advanced pancreatic cancer. 🔬 392 patients | Toripalimab + mFOLFIRINOX vs mFOLFIRINOX 📊 Key results: ✅ Event-free survival: 11.1 vs 9.6 months (HR 0.74; P = .007) ✅ Objective response: 30.1% vs 18.9% ✅ Overall survival: 20.6 vs 17.1 months (HR 0.81; P = .080) 🔥 The most interesting finding? In borderline resectable pancreatic cancer: • Median OS: 25.9 vs 16.2 months • HR 0.64, a 36% relative reduction in the hazard of death. ⚠️ But important caveats: • No clear survival benefit in locally advanced disease. • Overall survival benefit was not statistically significant in the full population. • Resection rates were virtually identical (42.3% vs 43.9%). • Single-center, open-label Phase II study. Subgroup findings need confirmation. 💡 My take: Perhaps the question is not whether immunotherapy works in pancreatic cancer, but WHEN in the disease course we introduce it. Promising signal, especially in borderline resectable disease, but not practice-changing yet. @oncoalert #PancreaticCancer #Immunotherapy #Oncology Full paper link in comment below ⬇️

🚨 50.7% pCR in resectable NSCLC! Could dual PD-1/VEGF blockade redefine perioperative immunotherapy? 📢 New Phase II trial in Nature Medicine evaluates ivonescimab, a bispecific PD-1 × VEGF antibody. 🔬 Study • 90 patients with stage II–IIIB NSCLC • Ivonescimab alone or with chemotherapy, followed by surgery and adjuvant ivonescimab 📊 Key results (ivonescimab + chemotherapy) ✅ MPR: 70.1% ✅ pCR: 50.7% ✅ R0 resection: 100% among operated patients ✅ 12-month EFS: 83.3% ⚠️ Grade ≥3 treatment-related AEs: 30.4% 🔥 The squamous NSCLC signal is particularly striking: • MPR: 81.5% • pCR: 61.1% No grade ≥3 hemorrhage reported, despite VEGF blockade. 💡 Why it matters Ivonescimab may deepen pathological responses beyond what has historically been observed with perioperative chemoimmunotherapy. ⚠️ Important caveat: Nonrandomized, noncomparative Phase II study. Pathological responses were assessed among patients undergoing surgery, and EFS remains immature. Cross-trial comparisons cannot establish superiority. 🎯 Verdict: Compelling early activity, especially in squamous NSCLC. Randomized Phase III evidence is essential before changing practice. @NatureMedicine @oncoalert #LungCancer #NSCLC #Immunotherapy Full paper link in comment below ⬇️

🚨 Are we overtreating early breast cancer with chemotherapy? A timely perspective in @JCO_ASCO revisits 4 landmark trials: MINDACT → TAILORx → RxPONDER → OPTIMA. The evolution of genomic-guided chemotherapy in HR+/HER2− breast cancer is fascinating. 🔹 MINDACT | MammaPrint High clinical risk ≠ automatic chemotherapy. Favorable genomic biology can support omission. 🔹 TAILORx | Oncotype DX Most node-negative patients with RS 11–25 can avoid chemotherapy. Younger women remain an important exception. 🔹 RxPONDER | Oncotype DX With 1–3 positive nodes and RS ≤25: • Postmenopausal: No meaningful chemotherapy benefit. • Premenopausal: Significant benefit persists. 🔹 OPTIMA | Prosigna (PAM50) The next frontier! ✅ Included patients with up to 9 positive nodes. ✅ ROR ≤60 guided chemotherapy omission. ✅ ~2/3 avoided chemotherapy. ✅ Genomic-guided treatment was noninferior at 3.9 years’ median follow-up. But here’s the BIG unanswered question: Does chemotherapy benefit younger women because of its cytotoxic effects, or because it suppresses ovarian function? OPTIMA mandated ovarian suppression in premenopausal participants and found no significant heterogeneity by menopausal status. This is hypothesis-generating, NOT definitive proof. 🔬 Next to watch: OFSET (NRG-BR009) and OPTIMA-YOUNG. 💡 My takeaway: The future isn’t simply identifying who can skip chemotherapy. It’s determining whether optimized endocrine therapy can replace chemotherapy in selected younger women. Excellent perspective by @YAbdouMD and Lisa Carey. @myesmo @ESMO_open @OncoAlert #BreastCancer #PrecisionOncology #ESMO26 Full paper link in comment below ⬇️